 |
|
Frequency of Fabry disease in chronic kidney disease patients including patients on renal replacement therapy in Korea
Eunjung Cho, Jung Tak Park, Tae-Hyun Yoo, Soo Wan Kim, Cheol Whee Park, Seung Seok Han, Yeong Hoon Kim, Young Joo Kwon
Kidney Res Clin Pract. 2024;43(1):71-81. Published online 2024 Jan 12 DOI: https://doi.org/10.23876/j.krcp.22.087
|
|
Citations to this article as recorded by
 Screening and diagnosis of Fabry disease in chronic kidney disease: the important role of globotriaosylsphingosine
Jung-ho Shin, Su Hyun Kim
Kidney Research and Clinical Practice.2024; 43(1): 1. CrossRef CRISPR/Cas9-mediated suppression of A4GALT rescues endothelial cell dysfunction in a fabry disease vasculopathy model derived from human induced pluripotent stem cells
Yoo Jin Shin, Seung Yun Chae, Hanbi Lee, Xianying Fang, Sheng Cui, Sun Woo Lim, Kang In Lee, Jae Young Lee, Can Li, Chul Woo Yang, Byung Ha Chung
Atherosclerosis.2024; 397: 118549. CrossRef Prevalence of Fabry Disease in Patients on Dialysis in France
Florence Sens, Laure Guittard, Bertrand Knebelmann, Olivier Moranne, Gabriel Choukroun, Valérie de Précigout, Cécile Couchoud, Isabelle Deleruyelle, Léa Lancelot, Liên Tran Thi Phuong, Thomas Ghafari, Laurent Juillard, Dominique P. Germain
International Journal of Molecular Sciences.2024; 25(18): 10104. CrossRef
|